AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8684407 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 1229
Study 8684407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terazosin and finasteride
Number of subjects: 1229
Study 8684407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study 2018208 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg/20 min
Number of subjects: 155
Study 2018208 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg/20 min
Number of subjects: 155
Study 2018208 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mg/kg/10 min
Number of subjects: 155
Study 6786069 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (400 +/- 80 mg/day)
Number of subjects: 10
Study 6786069 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (82 +/- 31 mg/day)
Number of subjects: 10
Study 6786069 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6786069 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 10
Study 6786069 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 10
Study 31637608 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Health Recovery Program (HHRP-A)
Number of subjects: 243
Study 31637608 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 243
Study 29533255 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Number of subjects: 40
Study 29533255 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dextrose
Number of subjects: 40
Study 29533255 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% dextrose
Number of subjects: 40
Study 29533255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 27777129 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg aspirin
Number of subjects: 10120
Study 27777129 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg aspirin
Number of subjects: 10120
Study 27777129 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10120
Study 27777129 — intervention group
Group type: COMPARATOR
Intervention: 100mg aspirin, 300mg aspirin, matched placebo
Number of subjects: 10120
Study 23870503 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDSUN questionnaire
Number of subjects: 609
Study 23870503 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race, BMI, suntan within the past year, sun exposure in the past 3 months, sunscreen use, and supplemental vitamin D intake
Number of subjects: 609
Study 23870503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake from supplements
Number of subjects: 609
Study 23870503 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics and behaviors
Number of subjects: 609
Study 22277663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg bolus)
Number of subjects: 100
Study 22277663 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg bolus + 16 mg in PCA)
Number of subjects: 100
Study 20530614 — intervention group
Group type: EXPERIMENTAL
Intervention: TES(60Hz)
Number of subjects: 20
Study 20530614 — intervention group
Group type: COMPARATOR
Intervention: TES(100Hz)
Number of subjects: 20
Study 18496393 — intervention group
Group type: COMPARATOR
Intervention: Rectoanal inhibitory reflex (RAIR) assessment with balloon distention (10 to 50 mL) in constipation patients
Number of subjects: 22
Study 18496393 — intervention group
Group type: COMPARATOR
Intervention: Volume of distention to achieve 50% relaxation in constipation patients
Number of subjects: 22
Study 18496393 — intervention group
Group type: COMPARATOR
Intervention: Percentage of relaxation as a diagnostic tool for constipation
Number of subjects: 22
Study 15925158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open blind technique (group A)
Number of subjects: 185
Study 15925158 — intervention group
Group type: COMPARATOR
Intervention: Limited open technique (group B)
Number of subjects: 185
Study 12180224 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine antisepsis (Group B)
Number of subjects: 167
Study 12180224 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis (1 g i.v. injection of cephradine at induction of anaesthesia) (Group C)
Number of subjects: 167
Study 12180224 — intervention group
Group type: COMPARATOR
Intervention: Control (saline soaked gauze at the urethral meatus) (Group A)
Number of subjects: 167
Study 10353581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 36
Study 10353581 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 36
Study 10353581 — intervention group
Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 36
Study 8845083 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 8845083 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 0
Study 2015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 0
Study 2015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (22 mg)
Number of subjects: 0
Study 2015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine and yohimbine
Number of subjects: 0
Study 2015177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 0
Study 6128596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 17
Study 6128596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31277532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy-injection technique with targeted three-point
Number of subjects: 140
Study 31277532 — intervention group
Group type: COMPARATOR
Intervention: Small needle knife therapy
Number of subjects: 140
Study 27571713 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Annurca apples per day
Number of subjects: 250
Study 27571713 — intervention group
Group type: COMPARATOR
Intervention: Red Delicious, Granny Smith, Fuji, Golden Delicious (one apple per day each)
Number of subjects: 250
Study 26263287 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker with diclofenac sodium
Number of subjects: 180
Study 26263287 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 180
Study 26263287 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 22884611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (MAS)
Number of subjects: 13
Study 22884611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22152089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 200/10 μg via metered-dose inhaler (MDI) BID
Number of subjects: 722
Study 22152089 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S) 250/50 μg via dry powder inhaler (DPI) BID
Number of subjects: 722
Study 19776771 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-aggregation with dipyridamole and aspirin
Number of subjects: 0
Study 17102242 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Oriented education management system for diabetes (POEM)
Number of subjects: 0
Study 15448954 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy (GCC)
Number of subjects: 13
Study 11695725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 100
Study 11695725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 100
Study 9222612 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work interventions
Number of subjects: 0
Study 9222612 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 9222612 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work activities
Number of subjects: 0
Study 8591949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin
Number of subjects: 0
Study 8591949 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine monotherapy (45 mg/kg over 3 days)
Number of subjects: 0
Study 2474057 — intervention group
Group type: EXPERIMENTAL
Intervention: LNH-84 regimen (ACVB) comprising doxorubicin 75 mg/m2, cyclophosphamide 1200 mg/m2, vindesine 2 mg/m2 x 2, bleomycin 10 mg x 2, prednisolone 60 mg/m2 x 5, followed by high-dose methotrexate, ifosfamide, etoposide, asparaginase, and cytarabine, with late intensification using AraCVmB.
Number of subjects: 737
Study 2474057 — intervention group
Group type: EXPERIMENTAL
Intervention: LNH-84 regimen with late intensification
Number of subjects: 737
Study 2474057 — intervention group
Group type: EXPERIMENTAL
Intervention: LNH-84 regimen
Number of subjects: 737
Study 949589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening with paired linguistic stimuli
Number of subjects: 60
Study 949589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening with nonverbal material
Number of subjects: 60
Study 949589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening with randomly interspersed verbal and nonverbal pairs
Number of subjects: 60
Study 31985275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 28
Study 31985275 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study 31985275 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 28
Study 31282921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (prednisolone acetate, 50 mg/d for 7 days) and other bundled interventions
Number of subjects: 816
Study 31282921 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the bundled intervention)
Number of subjects: 816
Study 31282921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (intervention group)
Number of subjects: 816
Study 25937159 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 148
Study 25937159 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 148
Study 23286834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of HMB-FA
Number of subjects: 20
Study 23286834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21909614 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite as a liner
Number of subjects: 85
Study 21909614 — intervention group
Group type: COMPARATOR
Intervention: Composite resin directly (Control)
Number of subjects: 85
Study 18697386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicular screw instrumentation at all pedicles in the fusion area (Group 1)
Number of subjects: 50
Study 18697386 — intervention group
Group type: COMPARATOR
Intervention: Partial pedicular screw instrumentation (Group 2)
Number of subjects: 50
Study 16219631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables Make the Marks intervention (school-based fruit and vegetable intervention with home economics component and parental involvement)
Number of subjects: 369
Study 16219631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables Make the Marks intervention
Number of subjects: 369
Study 16219631 — intervention group
Group type: COMPARATOR
Intervention: Control schools (10 schools)
Number of subjects: 369
Study 12688274 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyArm device (group 2)
Number of subjects: 40
Study 12688274 — intervention group
Group type: COMPARATOR
Intervention: Conventional Venturi mask (group 1)
Number of subjects: 40
Study 11197192 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing on school‐days with a 1,000 ppm chalk‐based fluoride toothpaste for two years
Number of subjects: 461
Study 11197192 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who brushed once a day or less)
Number of subjects: 461
Study 11197192 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental beliefs regarding time to check child's toothbrushing
Number of subjects: 461
Study 11197192 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing charts as an incentive
Number of subjects: 461
Study 8772758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with 40%, 50%, 65%, 80%, 30%/50% tilt
Number of subjects: 38
Study 8772758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with 65% tilt and 50‐ and 120‐microF capacitance
Number of subjects: 38
Study 8772758 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐microF capacitor
Number of subjects: 38
Study 8772758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with 50% tilt and 40%/50% tilt
Number of subjects: 38
Study 1505537 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D taper (4 days; n = 7)
Number of subjects: 25
Study 1505537 — intervention group
Group type: EXPERIMENTAL
Intervention: 8D taper (8 days; n = 6)
Number of subjects: 25
Study 1505537 — intervention group
Group type: COMPARATOR
Intervention: CON (control, 4 days rest; n = 6)
Number of subjects: 25
Study 1505537 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTAPER (non-taper, continued training; n = 6)
Number of subjects: 25
Study 6833021 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride, 5 grams qid during therapy
Number of subjects: 33
Study 6833021 — intervention group
Group type: COMPARATOR
Intervention: Diphenoxylate hydrochloride and atropine sulfate, 2.5‐20 mg per day (control) if diarrhea occurred
Number of subjects: 33
Study 30980177 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen plus risperidone
Number of subjects: 64
Study 30980177 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 64
Study 28847205 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (MOD-C)
Number of subjects: 44
Study 28847205 — intervention group
Group type: COMPARATOR
Intervention: Vigorous sprint-interval cycling (VIG-SIC)
Number of subjects: 44
Study 28847205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MOD-C and VIG-SIC
Number of subjects: 44
Study 26577506 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608
Study 26577506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 24215716 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of recombinant human follicle-stimulating hormone (rhFSH) 300 IU on alternate days for ≥4 months
Number of subjects: 45
Study 24215716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21340657 — intervention group
Group type: EXPERIMENTAL
Intervention: Trolamine emulsion (prophylactic, every 8 hours, 4 hours apart from radiotherapy)
Number of subjects: 30
Study 21340657 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive care (control group)
Number of subjects: 30
Study 21340657 — intervention group
Group type: EXPERIMENTAL
Intervention: Trolamine emulsion
Number of subjects: 30
Study 18513887 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with regional hyperthermia (HT) using a higher RF-output power (>/=1,200 W)
Number of subjects: 35
Study 18513887 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional hyperthermia (HT)
Number of subjects: 35
Study 17822466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention using vacuum erection device (VED) starting 1 month after RP, daily for 10 min/day for 5 months.
Number of subjects: 28
Study 17822466 — intervention group
Group type: COMPARATOR
Intervention: Control group using VED starting 6 months after RP.
Number of subjects: 28
Study 16246664 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality female condom
Number of subjects: 60
Study 16246664 — intervention group
Group type: COMPARATOR
Intervention: Reddy female condom
Number of subjects: 60
Study 12035874 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting calcium channel blockers (CCBs) such as nifedipine GITS, nitrendipine, and diltiazem
Number of subjects: 4500
Study 12035874 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 4500
Study 9697672 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic urodilatin (URO) infusion at a low dose of 20 ng x kg(‐1) x min(‐1) for 60 minutes
Number of subjects: 24
Study 9697672 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 10586205 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (300 U/kg) three times a week for 8 weeks
Number of subjects: 32
Study 10586205 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo + G‐CSF (1 microg/kg) three times a week for 8 weeks (added if PR or NR after rHuEpo)
Number of subjects: 32
Study 10586205 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo administration
Number of subjects: 32
Study 10586205 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian‐American response score > +1
Number of subjects: 32
Study 10586205 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian‐American response score <= 1
Number of subjects: 32
Study 2518952 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus vaccine
Number of subjects: 0
Study 2518952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented virus vaccine
Number of subjects: 0
Study 750603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (2 g)
Number of subjects: 10
Study 750603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31639321 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no PrEP)
Number of subjects: 144
Study 31639321 — intervention group
Group type: COMPARATOR
Intervention: Baseline CARS measure
Number of subjects: 144
Study 27560549 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (8 or more cycles)
Number of subjects: 1059
Study 27560549 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (more than 10 cycles)
Number of subjects: 1059
Study 27560549 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (8 to 10 cycles)
Number of subjects: 1059
Study 27560549 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (5 to 7 cycles)
Number of subjects: 1059
Study 27560549 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (4 or fewer cycles)
Number of subjects: 1059
Study 25201903 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure group (Subgroup g: 3 bars-power levels/1 frequency application)
Number of subjects: 100
Study 25201903 — intervention group
Group type: COMPARATOR
Intervention: Stapler group
Number of subjects: 100
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS V285 at 0.4%
Number of subjects: 42
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS V35 at 99%
Number of subjects: 42
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS V240 at 63%
Number of subjects: 42
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS V35 at 95%
Number of subjects: 42
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS V265 at 24%
Number of subjects: 42
Study 23466360 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS V35 at 99.5%
Number of subjects: 42
Study 21519001 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 120
Study 21519001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20053262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (two explanatory illustrations)
Number of subjects: 80
Study 20053262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (four explanatory illustrations)
Number of subjects: 80
Study 20053262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (5-minute video and handling)
Number of subjects: 80
Study 16963041 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with PCOS
Number of subjects: 38
Study 16963041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose, fasting insulin, body mass index, and free T in patients with PCOS
Number of subjects: 38
Study 16963041 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin
Number of subjects: 38
Study 16963041 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameters controlled for body mass index
Number of subjects: 38
Study 15690112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation stage of change
Number of subjects: 181
Study 15690112 — intervention group
Group type: COMPARATOR
Intervention: Contemplation stage of change
Number of subjects: 181
Study 11400799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN
Number of subjects: 19
Study 11400799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9417802 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma delta T cell expansion in patients with CP (11.1 +/- 11.0%)
Number of subjects: 205
Study 9417802 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent gamma delta T cell expansion over 15% in 15 patients
Number of subjects: 205
Study 9417802 — intervention group
Group type: EXPERIMENTAL
Intervention: V gamma II/V delta 2-dominant expansion
Number of subjects: 205
Study 9417802 — intervention group
Group type: EXPERIMENTAL
Intervention: V delta 1-dominant expansion
Number of subjects: 205
Study 9417802 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual expansions of V delta 4 and V delta 6
Number of subjects: 205
Study 8494429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 109
Study 8494429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 3732367 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur (theophylline only)
Number of subjects: 12
Study 3732367 — intervention group
Group type: COMPARATOR
Intervention: Phyllocontin (aminophylline)
Number of subjects: 12
Study 30322782 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill workstations for optional use
Number of subjects: 80
Study 30322782 — intervention group
Group type: COMPARATOR
Intervention: Sit-stand desks as usual (Control)
Number of subjects: 80